Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Chineo Medical Technology Co. Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, so the workload is distributed but not evenly across the examination assignments.
XIAO, YAN is the busiest examiner, with 2 pending matters. Counsel should prioritize coordination for that examiner’s matters while maintaining separate claim and prior-art analyses for the remaining assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XIAO, YAN | 2 | 67.3% | +52.7% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033483 | MODIFIED IMMUNE CELL AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| 17429835 | ADJUVANT CAPABLE OF PROMOTING EXPANSION OF IMMUNE CELLS IN VIVO | JOHANSEN, PETER N. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18518539 | MODIFIED IMMUNE CELLS AND USES THEREOF | XIAO, YAN | — |
| 18518534 | MODIFIED IMMUNE CELLS AND USES THEREOF | XIAO, YAN | — |
| 18033483 | MODIFIED IMMUNE CELL AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| 17429835 | ADJUVANT CAPABLE OF PROMOTING EXPANSION OF IMMUNE CELLS IN VIVO | JOHANSEN, PETER N. | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1643 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18518539 | MODIFIED IMMUNE CELLS AND USES THEREOF | XIAO, YAN | 1642 | §102DP | Non-Final OA | — | Pending | Nov 23, 2023 |
| 18518534 | MODIFIED IMMUNE CELLS AND USES THEREOF | XIAO, YAN | 1642 | §102Other | Non-Final OA | — | Pending | Nov 23, 2023 |
| 18033483 | MODIFIED IMMUNE CELL AND USE THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §102§103 | Final Rejection | — | Pending | Oct 23, 2023 |
| 17429835 | ADJUVANT CAPABLE OF PROMOTING EXPANSION OF IMMUNE CELLS IN VIVO | JOHANSEN, PETER N. | 1644 | §102§103 | Final Rejection | — | Pending | Mar 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChineo Medical Technology Co. Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Yan Xiao has the most, with 2 of Chineo Medical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
